SCHEMBL2174657

SCHEMBL2174657

COc1cccc2cc(S(=O)(=O)Cl)sc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.72
TRPV4 Q9HBA0 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
LMNA P02545 1/20 0.38
RECQL P46063 1/20 0.38
ALDH1A1 P00352 3/20 0.37
CHRNA7 P36544 3/20 0.37
NPC1 O15118 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTR3A P46098 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PFKFB4 Q16877 2/20 0.35
PFKFB3 Q16875 1/20 0.35
CYP2A6 P11509 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175150 0.84 CA2 (0.53) CA2LMNAALDH1A1CHRNA7HTR3A
SCHEMBL2173848 0.84 CA2 (1.00) CA2CA12CA1CA9KMT2A
SCHEMBL2175458 0.80 CA2 (0.48) CA2TRPV4LMNAALDH1A1SMN1; SMN2
SCHEMBL2176018 0.80 CA2 (0.46) CA2CA12CA1CA9ALDH1A1
SCHEMBL2175456 0.79 CA2 (0.47) CA2KMT2AMEN1LMNANPC1
SCHEMBL2175480 0.78 HDAC3 (0.49) CA2KMT2AMEN1ALDH1A1CHRNA7
SCHEMBL2166154 0.72 CA2 (0.42) CA2KMT2AMEN1RECQLALDH1A1
SCHEMBL146428 0.72 CA2 (0.56) CA2CA12CA1CA9KMT2A
SCHEMBL4805151 0.72 CA2 (0.56) CA2CA12CA1CA9KMT2A
SCHEMBL5542286 0.70 CA2 (0.54) CA2CA12CA1CA9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973051-B2 Aminothiazoles as FBPase inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2011-07-05 US disclosed
EP-2227468-A1 AMINOTHIAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-15 EP disclosed
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 US disclosed
WO-2009068467-A1 AMINOTHIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES FBP1, SLC5A1, DPP4 CA2 1616/4885TRPV4 4491/4885CA12 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.